Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.

被引：0
|
作者：
Kayser, Simone
Icheva, Vanya
Stevanovic, Stefan
Siebert, Nikolai
Feucht, Judith
Lode, Holger N.
Handgretinger, Rupert
Feuchtinger, Tobias
机构：
[1] Univ Childrens Hosp, Tubingen, Germany
[2] Univ Tubingen, Dept Immunol, Inst Cell Biol, Tubingen, Germany
[3] Univ Med Greifswald, Greifswald, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Univ Med Ctr, Greifswald, Germany
[5] Univ Munich, Dr von Haunersches Kinderspital, Dept Pediat Hematol Oncol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3029
引用
收藏
页数：1
相关论文
共 50 条
  • [41] RELAPSED/REFRACTORY NEUROBLASTOMA PATIENTS RESPOND TO ANTI GD2 ANTIBODY CH14.18/CHO DELIVERED BY LONG-TERM INFUSION COMBINED WITH INTERLEUKIN-2 AND SHOW IMPROVED SURVIVAL RATES COMPARED TO HISTORICAL CONTROLS
    Lode, H.
    Valteau-Couanet, D.
    Manzitti, C.
    Gray, J.
    Castel, V.
    Yaniv, I.
    Siebert, N.
    Jensen, C.
    Endres, S.
    Pill, L.
    Eger, C.
    Seidel, D.
    Juettner, M.
    Kietz, S.
    Ehlert, K.
    Janzek, E.
    Loibner, H.
    Mueller, I.
    Ladenstein, R.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S224 - S225
  • [42] Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
    Ladenstein, Ruth
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Yaniv, Isaac
    Laureys, Genevieve
    Brock, Penelope
    Michon, Jean Marie
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Schreier, Guenter
    Loibner, Hans
    Ambros, Peter
    Holmes, Keith
    Castellani, Maria Rita
    Gaze, Mark N.
    Garaventa, Alberto
    Pearson, Andrew D. J.
    Lode, Holger N.
    LANCET ONCOLOGY, 2018, 19 (12): : 1617 - 1629
  • [43] Neuroblastoma patients with high-affinity FCGR2A,-3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
    Siebert, Nikolai
    Jensen, Christian
    Troschke-Meurer, Sascha
    Zumpe, Maxi
    Juettner, Madlen
    Ehlert, Karoline
    Kietz, Silke
    Mueller, Ina
    Lode, Holger N.
    OncoImmunology, 2016, 5 (11):
  • [44] Phase I/IIa multicenter trial for high-risk and recurrent neuroblastoma: Anti-GD2 antibody (ch14.18) immunotherapies using M-CSF or G-CSF
    Kawamoto, Hiroshi
    Yoshimura, Kenichi
    Kimura, Toshimi
    Nitani, Chika
    Hara, Junichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) plus Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
    Yu, Alice L.
    Gilman, Andrew L.
    Ozkaynak, M. Fevzi
    Naranjo, Arlene
    Diccianni, Mitchell B.
    Gan, Jacek
    Hank, Jacquelyn A.
    Batova, Ayse
    London, Wendy B.
    Tenney, Sheena C.
    Smith, Malcolm
    Shulkin, Barry L.
    Parisi, Marguerite
    Matthay, Katherine K.
    Cohn, Susan L.
    Maris, John M.
    Bagatell, Rochelle
    Park, Julie R.
    Sondel, Paul M.
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2179 - 2189
  • [46] Phase I bridging study of ch14.18/CHO long-term infusion in recurrent or refractory neuroblastoma patients in Japan.
    Takahashi, Yoshiyuki
    Narita, Atsushi
    Siebert, Nikolai
    Nishio, Nobuhiro
    Xu, Yinyan
    Muramatsu, Hideki
    Hama, Asahito
    Kamijo, Takehiko
    Nakazawa, Atsuko
    Hosoi, Hajime
    Kinoshita, Yoshiaki
    Shimizu, Shinobu
    Kato, Katsuyoshi
    Mizuno, Masaaki
    Loibner, Hans
    Tajiri, Tatsuro
    Nakagawara, Akira
    Ladenstein, Ruth
    Lode, Holger N.
    Kojima, Seiji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Early detection of response to therapy: Reduction of binding of the anti-GD2 antibody ch14.18 to SH-SY5Y neuroblastoma cells precedes retinoic acid effects on cell growth
    Dearling, Jason
    Voss, Stephan
    Treves, S. Ted
    Packard, Alan
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [48] Immunotherapy with Anti-GD2 Antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN Trial Improves Outcome of High-Risk Neuroblastoma Patients Compared to Historical Controls
    Ladenstein, R.
    Poetschger, U.
    Valteau-Couanet, D.
    Gray, J.
    Luksch, R.
    Castel, V.
    Ash, S.
    Laureys, G.
    Owens, C.
    Trahair, T.
    Chan, G. C. F.
    Ruud, E.
    Schroeder, H.
    Beck-Popovic, M.
    Loibner, H.
    Schreier, G.
    Ambros, P.
    Sarnacki, S.
    Boterberg, T.
    Lode, H.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S53 - S54
  • [49] Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma.
    Suzuki, Maya
    Cheung, Irene Y.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.
    Ladenstein, Ruth Lydia
    Poetschger, Ulrike
    Couanet, Dominique Valteau
    Gray, Juliet
    Luksch, Roberto
    Castel, Victoria
    Ash, Shifra
    Laureys, Genevieve
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Loibner, Hans
    Schreier, Guenter
    Ambros, Peter F.
    Sarnacki, Sabine
    Boterberg, Tom
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345